Applied Therapeutics rises on interim late-stage data for hereditary disease drug

Applied Therapeutics

15/02/2024 13:22

** Shares of drug developer Applied Therapeutics  APLT.O 
rise 11.9% to $3 premarket
    ** Co announced interim results from its ongoing late-stage
study testing its experimental drug to treat a type of
hereditary condition called Sorbitol Dehydrogenase deficiency
(SORD deficiency)
    ** SORD deficiency causes an inability to process or break
down a type of sugar called sorbitol resulting in loss of
mobility 
    ** The drug, govorestat, showed statistically significant
reductions in sorbitol levels compared to placebo in patients
over 12 months of treatment 
    ** The drug also helped in improving physical functions in
patients with the condition
    ** Co will evaluate patients on the drug again after 24
months with the main goal of assessing walking speed of patients
with the disease 
    ** Stock more than doubled in the last 12 months  

 (Reporting by Sneha S K)
 ((Sneha.SK@thomsonreuters.com;))